[Atrial fibrillation and thromboembolic events prevention. State of the art].
Matteoli, S
[Atrial fibrillation and thromboembolic events prevention. State of the art]. [electronic resource] - Minerva cardioangiologica Feb 2001 - 1-13 p. digital
Publication Type: Comparative Study; Editorial; English Abstract; Review
0026-4725
Age Factors
Aged
Aged, 80 and over
Anticoagulants--therapeutic use
Aspirin--therapeutic use
Atrial Fibrillation--complications
Controlled Clinical Trials as Topic
Electric Countershock
Fibrinolytic Agents--therapeutic use
Humans
Middle Aged
Multivariate Analysis
Platelet Aggregation Inhibitors--therapeutic use
Prevalence
Prospective Studies
Randomized Controlled Trials as Topic
Rheumatic Heart Disease--complications
Risk Factors
Stroke--epidemiology
Thromboembolism--etiology
Warfarin--therapeutic use
[Atrial fibrillation and thromboembolic events prevention. State of the art]. [electronic resource] - Minerva cardioangiologica Feb 2001 - 1-13 p. digital
Publication Type: Comparative Study; Editorial; English Abstract; Review
0026-4725
Age Factors
Aged
Aged, 80 and over
Anticoagulants--therapeutic use
Aspirin--therapeutic use
Atrial Fibrillation--complications
Controlled Clinical Trials as Topic
Electric Countershock
Fibrinolytic Agents--therapeutic use
Humans
Middle Aged
Multivariate Analysis
Platelet Aggregation Inhibitors--therapeutic use
Prevalence
Prospective Studies
Randomized Controlled Trials as Topic
Rheumatic Heart Disease--complications
Risk Factors
Stroke--epidemiology
Thromboembolism--etiology
Warfarin--therapeutic use